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Abstract
Background: Advanced esophageal squamous cell cancer (ESCC) is frequently diagnosed in elderly patients. The
impact of 2nd line chemotherapy is poorly defined. Recent data demonstrated effectiveness of checkpoint
inhibitors in different squamous cell carcinomas. Therefore, we assess combined nivolumab/ipilimumab as 2nd line
therapy in elderly ESCC patients.
Methods: RAMONA is a multicenter open-label phase II trial. The primary objective is to demonstrate a significant
survival benefit of nivolumab/ipilimumab in advanced ESCC compared to historical data of standard chemotherapy.
Primary endpoint is therefore overall survival (OS). Major secondary objective is the evaluation of tolerability. Time
to QoL deterioration will thus be determined as key secondary endpoint. Further secondary endpoints are tumor
response, PFS and safety. We aim to recruit a total of n = 75 subjects that have to be > 65 years old. Eligibility is
determined by the geriatric status (G8 screening and Deficit Accumulation Frailty Index (DAFI)). A safety assessment
will be performed after a 3 cycle run-in phase of nivolumab (240 mg Q2W) to justify escalation for eligible patients
to combined nivolumab (240 mg Q2W) and ipilimumab (1 mg/kg Q6W), while the other patients will remain on
nivolumab only. RAMONA also includes translational research sub-studies to identify predictive biomarkers,
including PD-1 and PD-L1 evaluation at different time points, establishment of organoid cultures and
microbiome analyses for response prediction.
Discussion: The RAMONA trial aims to implement checkpoint inhibitors for elderly patients with advanced
ESCC as second line therapy. Novel biomarkers for checkpoint-inhibitor response are analyzed in extensive
translational sub-studies.
Trial registration: EudraCT Number: 2017–002056-86; NCT03416244, registered: 31.1.2018.
Keywords: Esophageal squamous cell cancer, Elderly, Comprehensive geriatric assessment, Checkpoint
inhibitors, Personalized medicine, Geriatric oncology
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Background
ESCC is the sixth leading cause of cancer-related death
worldwide [1]. The disease is frequently diagnosed in ad-
vanced tumor stages and in elderly patients [1, 2].
Efficacy of chemotherapy in advanced ESCC is still poorly
defined. While most patients undergo chemotherapy and/
or chemo-radiation in first line according to the CROSS
protocol using Paclitaxel and Carboplatin, effectiveness of
second-line chemotherapy is discouraging [3, 4]. However,
very recently Kojima et al. reported that pembrolizumab
significantly improved OS compared to chemotherapy (pac-
litaxel, docetaxel or irinotecan) in patients with advanced
esophageal or esophagogastric junction carcinoma whose
tumors express PD-L1 (Combined Positive Score [CPS]
≥10, regardless of histology) (median 9.3 vs 6.7 mo; HR
0.69; 95% CI 0.52–0.93; P = 0.0074). OS at 12months was
43% vs 20%, respectively. (KEYNOTE 181) [5].
Immunotherapy with antibodies against immune
checkpoints like PD-1/PD-L1 represents a new treat-
ment opportunity with relatively little side effects and
first promising results in the treatment of squamous
cell carcinoma patients [6–8]. With respect to esopha-
geal cancer, preliminary results from an Asian study in-
dicate efficacy of nivolumab [9]. From 64 heavily
pre-treated patients, 11 (17, 95% CI 10–28) had an ob-
jective response and 16 (25, 95% CI 16–37) demon-
strated stable disease. The median overall survival was
10.8 months (IQR 4.9–14.3) in this trial population (un-
selected for PD-L1 expression status). Long-term sur-
vival was also improved by pembrolizumab as described
by Doi et al. [10].
Furthermore, the CheckMate 012 trial demonstrated
that overall response rates could be doubled when PD-1 in-
hibitor nivolumab was combined with CTLA-4-inhibitor
ipilimumab in advanced NSCLC patients [11]. In this trial,
grade 3 and 4 adverse events were reported to occur in
33% of the patients treated with the combination therapy
(nivolumab 3mg/kg Q2W and ipilimumab 1mg/kg Q6W).
In the checkmate 032 in turn (nivolumab 3mg/kg Q2W
and ipilimumab 1mg/kg Q3W), treatment related adverse
events of grade 3 and 4 were only slightly enhanced when
compared to nivolumab monotherapy (13% vs. 19%) [12].
There is an increasing need for improved treatment
strategies for elderly ESCC patients. These strategies
have to acknowledge the challenges of functional limita-
tions and comorbidities in this increasing population.
With increasing age, elderly patients develop chronic
diseases and different comorbidities that may affect per-
son’s capabilities, functional reserve and life expectancy
[13]. However, assessment of these characteristics in the
elderly population is time-consuming, therefore new as-
sessment and screening tools are being developed. The
poor knowledge of the role of chemotherapy and im-
munotherapy in these individuals, due to lack of
enrolment of these patients in clinical trials, demands
for novel concepts of clinical trials specifically designed
for elderly patients.
With the RAMONA trial, we aim to address this high
medical need by assessing nivolumab and ipilimumab in
combination as second-line therapy of advanced ESCC
in the elderly population. Patient eligibility will be
assessed by geriatric screening tools in this trial. More-
over, we aim to establish novel biomarkers for check-
point inhibition by extensive translational sub-studies.
Methods/design
Study design
RAMONA is a multicenter open-label phase II trial
conducted in 34 centers in Germany (for overviews
please refer to Additional file 1: Table S1). Key inclu-
sion criteria are
 age ≥ 65 years at time of recruitment
 histologically approved diagnosis of advanced ESCC
 progression after front line treatment (including
chemo-radiation with carboplatin/paclitaxel or
others)
A screening phase is used to determine the eligibility
of a patient and may last up to 4 weeks before initiation
of treatment. Eligibility and the geriatric status of poten-
tial patients will be assessed using the G8 screening tool
and the Deficit Accumulation Frailty Index (DAFI). Pa-
tients are recruited independent of their PD-1 or PD-L1
expression status.
The dosing rationale for the study is based on Kudo et
al. [9] and Hellmann et al. [11]. The treatment phase be-
gins with 2nd-line nivolumab monotherapy safety run-in
(240 mg fixed dose Q2W). Based on reports by Kähler et
al., [14, 15] a safety assessment will be performed after 3
cycles of nivolumab monotherapy (6 weeks), during
which the investigator will decide if a patient is eligible
to receive nivolumab/ipilimumab combination therapy
(Nivo 240mg fixed dose Q2W; ipilimumab 1mg/kg
Q6W; arm A) or continues nivolumab monotherapy
(240 mg fixed dose Q2W; arm B). This safety assessment
was added due to the substantial comorbidities in most
ESCC patients which may increase adverse events as
compared to patients with other carcinomas and which
might e.g. counteract treatment escalation. Only those
patients with toxicities grade ≤ 2 will be escalated. In
both arms, treatment continues until progressive disease
or intolerable toxicity or withdrawal of consent or death.
After another 3 cycles of treatment in both arms
(approx.12 weeks from first dose) a restaging examin-
ation by radiologic imaging will be performed, which is
repeated every four treatment cycles thereafter.
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Treatment within the context of the study is limited to
2 years.
Samples for translational research are gathered at
different time points, i.e. screening/baseline (no ther-
apy), safety assessment (after 3 cycles of nivolumab
monotherapy) and restaging (after 3 cycles in treat-
ment arm A or arm B). The study design is illus-
trated in Fig. 1.
Study objectives
The primary objective of this trial is to demonstrate a
significant survival benefit of the combination therapy
with nivolumab/ipilimumab treatment in advanced
ESCC compared to historical data of standard chemo-
therapy regimens [4].
Secondary objectives:
Tolerability of nivolumab as single agent and in com-
bination with ipilimumab will be investigated in terms of
QoL. Hence, a key secondary endpoint ‘time to QoL de-
terioration’ will be implemented.
Further secondary objectives are the assessment of
additional efficacy and safety parameters of an intensi-
fied immunotherapy regimen and the assessment and
exploration of the predictive value of structured geriatric
assessments for treatment-emergent toxicities and treat-
ment discontinuation.
Measurements
For patient screening, the G8 screening tool and the
Deficit Accumulation Frailty Index (DAFI) will be used.
Patients with G8 score > 14 will be stratified as non-frail
and can be directly included into to study (GoGo). If G8
scores ≤14 (frail), the DAFI questionnaire needs to be
performed. DAFI-indices between 0.2 and 0.35 qualify
patients as SlowGo enabling the PI to decide whether a
patient is eligible or cannot participate. DAFI index
≥0.35 is defined as exclusion criterion.
In terms of safety, the screening includes an intensified
assessment of cardiac co-morbidities using echocardiogram
and measurement of cardiac enzymes (e.g. troponin-I).
QoL will be assessed by the EORTC questionnaires
QLQ-C30 and ELD14.
Safety assessment
Procedures to be conducted during the treatment phase
of the study include a safety assessment after 3 weeks (3
cycles) of nivolumab monotherapy. A study subject is eli-
gible to escalate to nivolumab/ipilimumab combination
therapy if I) the study subject has sufficient cardiac
Fig. 1 Study scheme. Patients may be escalated to nivolumab/ipilimumab combination therapy after a 3 cycle nivolumab-only run-in phase and
positive safety assessment. GA: geriatric assessment (G8 / DAFI). ***: treatment escalation according to safety assessment results (please see full
protocol). **: Chemotherapy (+/− radiotherapy) (e.g. CROSS, FLOT or similar protocols) OR any palliative systemic chemotherapy. * Stage 4 OR
stage 3 non-responder to radio-chemotherapy OR any relapse after chemo-radiation OR any relapse after surgery if patient is ineligible or
intolerant to standard frontline therapy OR refuses other treatment. PD1: off study despite post-progression ipi/nivo in case of toxicity and/or
clinical deterioration. PD2: off study if confirmed progression according to Recist criteria V 1.1 or non-response according to immune-related
response criteria. Ipilimumab 1mg/kg IV Q6W. Nivolumab 240mg IV Q2W. Restaging (incl. Endoscopic biopsies +PD-L1 staining)
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functional reserve determined by cardiac echo (less than
10% decline in ejection fraction compared to baseline as-
sessment), II) no clinically significant abnormal troponin
or ECG and III) the study subject is potentially benefitting
from treatment escalation according to the judgment of
the investigator.
End of treatment
All subjects will be followed for survival until the end of
the study, regardless of further treatments, or until the
sponsor ends the study (follow-up extension phase).
The following procedures will be performed during
follow-up every 6 weeks for the first year of follow-up,
and every 8–12 weeks thereafter:
 assessment of survival status
 recording of all anti-cancer treatments
 recording of all AEs and SAEs for 100 days after last
dosing





 Time to QoL deterioration defined as a loss of




 ORR according to RECIST 1.1 and immune related
response criteria (modified RECIST)
 Duration of Response (DOR)
 Duration of treatment
 cumulative dose intensity
 QoL (EORTC QLQC30 and ELD14)
 AEs/SAEs, toxicities according to CTC criteria v4.0
 Geriatric assessments:
 Evaluation of the predictive value of the GA
containing tests (DAFI, G8-Questionaire etc.) for
the occurrence of ≥ grade 3 toxicities
 Predictive value of the assessed geriatric tests for
treatment discontinuation
 Translational research at different time points
(screening, safety assessment and first restaging)
 PD-1-PD-L1 expression in tumor tissue before and
during treatment
 predictive biomarkers in tumor tissue (pre-treatment
and re-biopsies) and blood
 establishment of organoid cultures from tumor
tissue specimens
 Response prediction by microbiome assessment
Study setting
Patients will be recruited at 34 selected study sites in
Germany including academic hospitals, community
clinics and practitioner to achieve adequate participant
enrolment. A list of study sites can be obtained from the
corresponding author of this manuscript. Protocol modi-
fications will be communicated to relevant parties upon
ethics approval.
Data collection
Data for this study will be recorded via eCRF by the
site from the source documents according to standard
operational procedures. Data are reviewed and
checked for omissions, apparent errors, and values re-
quiring further clarifications using computerized
(automatic) and/or manual procedures. Accurate and
reliable data collection will be assured by verification
and cross–check of the eCRF against the investigator’s
records by the study monitor. Data will be recorded
and reported until the last subject will have com-
pleted the trial. Informed consent or assent forms in-
cluding additional informed consent/assent forms for
participation in the RAMONA translational research
program will remain at the respective study sites.
Confidentiality of personal information is protected
by adherence to the European GDPR.
Statistical analysis and sample size
It is hypothesized that nivolumab and ipilimumab will
increase overall survival. It is assumed that an immuno-
therapy approach consisting of a nivolumab monother-
apy in conjunction with a safety guided treatment
escalation to a nivolumab/ipilimumab combination regi-
men increases the 1-year overall survival rate by a mar-
gin of 13% compared to historical control for standard
chemotherapy (i.e. nivolumab monotherapy followed by
a conditional nivolumab + ipilimumab therapy 1-yr-OS
= 30% vs CTx-control 1-yr-OS = 17%) [4]. Based on
these assumptions, and an exponential shape of the sur-
vival curve, a one-sided, one-sample log rank test calcu-
lated from a sample of 69 subjects achieves 90.3% power
at an alpha = 0.05 one-sided significance level to detect a
proportion surviving of 0.3 in the experimental group
when the proportion surviving in the historic control
group is 0.17. These proportions surviving are for a
period of 12 month (1-year-OS rate). Subjects are ac-
crued for a period of 12 month. Follow-up continues for
a period of 24 month after the last subject is added.
The probability that a subject experiences an event
during the study is 0.9477. The expected number of
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events during the study is 65. To compensate for un-
informative drop-outs a total of N = 75 subjects need
to be recruited. All patients, both on monotherapy
and on combination therapy, are subject to statistical
ITT analysis.
Discussion
In the CROSS trial, van Hagen et al. demonstrated
that first-line neoadjuvant chemoradiation using car-
boplatin and paclitaxel is a highly effective regimen
for locally advanced ESCC, leading to patients´ overall
survival of more than 50 months in single cases (me-
dian DOR of 15 months) [3]. This approach is also
considered effective as definite chemoradiotherapy for
advanced ESCC patients who are not candidates for
subsequent surgery [16] and therefore commonly used
in Germany. In these patients, second line treatment
with paclitaxel is not an option. However, treatment
options after chemoradiation with platin derivatives
and taxanes for patients with recurrent cancers are
limited. Thallinger and coworkers convincingly dem-
onstrated that 2nd line therapy for these patients is
un-standardized [4]. Clinical trials focusing on 2nd
line chemotherapy for ESCC patients showed frustrat-
ing response rates, enhanced toxicity rates and poor
overall survival, mostly limited to 6–8 months [4].
Furthermore, majority of ESCC patients are elder per-
sons [17] with significant co-morbidities which in the
clinical practice typically renders these patients ineli-
gible for poly-chemotherapy.
To address this issue, the aim of the RAMONA
trial is to evaluate a promising new second line ther-
apy option for elderly ESCC patients. Nivolumab as
immunotherapeutical agent blocks interaction of PD-1
molecules expressed by tumor-specific T-cells with its
ligand PD-L1 on tumor cells, as reviewed in [18].
PD-L1 expression seems to be significantly increased
in ESCC with age and is associated with poor prog-
nosis [19]. Pooled analysis of CheckMate 017 and
checkmate 057 studies demonstrated, that higher
PD-L1 expression levels were associated with greater
OS benefit with nivolumab (HR, 0.42; 95% CI, 0.28 to
0.63) in patients with ≥50% PD-L1 expression, but a
benefit was still observed in patients with < 1% PD-L1
expression (HR, 0.78; 95% CI, 0.61 to 0.99) [20].
However, here effects seem to more prominent in
non-squamous NSCLC. Antonia and colleagues very
recently presented new data hinting towards improved
ORR in correlation with PDL-1 expression levels
upon nivolumab/ipilimumab combination therapy as
compared to nivolumab monotherapy (Chicago Multi-
disciplinary Symposium in Thoracic Oncology, 2016,
[11]). Despite further promising results indicating a
correlation of good ORR with expression of PD-L1 in
lung cancer (PD1 expression ≥1% ORR 57% vs. 28%)
[11, 21], the predictive value of PD-1/PD-L1 expres-
sion for nivolumab-based therapies is not fully under-
stood in most tumor entities. Therefore, we
implemented a translational part into the trial moni-
toring PD-1/PD-L1 expression rates during the course
of treatment.
Checkpoint-inhibitor treatments combine several ad-
vantages, which are especially interesting with regard
to ESCC treatment approaches. Firstly, promising
overall survival has been reported in squamous cell
carcinoma patients of different entities, pointing to-
wards a rationale to test efficacy also in ESCC [6, 11,
22–24]. Secondly, antitumor activity of checkpoint in-
hibitors was shown when used after radiation-based
treatments, which is commonly also performed in
ESCC treatment. For instance, in a randomized phase
III trial including stage II NSCLC patients (i.e. patient
that undergo surgery with curative intent), Antonia
and coworkers demonstrated that PFS was increased
by durvalumab treatment after chemotherapy/radio-
therapy compared to chemotherapy/radiotherapy
alone [25]. In line, NSCLC patients treated with pem-
brolizumab showed longer PFS (HR 0.56 [95% CI
0.34–0.91], p = 0.019) and increased OS (HR 0.58
[95% CI 0.36–0.94], p = 0.026) if they had received
any radiotherapy as compared to non-radiated pa-
tients [26]. An association of radiotherapy with im-
proved rates of index lesion response in 68% of
melanoma patients treated with ipilimumab [27] fur-
ther underline possible synergistic effects of radiation
and immunotherapy on local on distant tumor control
as reviewed in [28].
Kudo et al. reported that even for heavily pretreated
ESCC patients, immunotherapy with nivolumab alone
prolonged overall survival of Asian patients by median
10.8 months (95% CI 7·4–13·3) [9]. Additionally, the risk
profile of ESCC patients [1, 29–32] in part overlaps with
that of NSCLC patients who are often heavy smokers. In
line, available data reveals that especially heavy smokers
seem to profit from immunotherapy (Objective response:
current and former smokers vs never-smokers (46% [30
of 65] vs 27% [3 of 11]) [11].
ESCC is most frequently diagnosed between 65 and
74 years [17], defining the patient cohort as mostly eld-
erly with per se accumulated co-morbidities, impaired
pharmacokinetics and a potentially declined functional
reserve [13]. To objectify the functional reserve of the
patients and its impact on treatment outcome, a com-
prehensive geriatric assessment (CGA) is recommended
[33]. However, CGA is time consuming and rarely feas-
ible in clinical practice. Thus, we decided to assess the
vulnerability of our study subjects by the G8 ques-
tionnaire and implement the more complex DAFI
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assessment only for patients below G8 cut-off (≤14
points). The DAFI is a condensed, validated CGA
with 51 items lasting approximately 30 min of which
> 80% can be self-reported by the patient [34]. Based
on Cohen et al., we estimated that ~ 40% of the pa-
tients will belong to a pre-frail group with DAFI indi-
ces between 0.2 and 0.35. These patients can enter
the RAMONA study upon investigator’s decision as
immune-oncological treatments are known to be
well-tolerated [11]. Even for combined nivolumab/ipi-
limumab therapy, grade ≥ 3 toxicities are reported to
occur in only 33% in NSCLC [11]. As the CheckMate
Trial 214 revealed grade 3 and 4 toxicities in up to
46% of the patients with advanced renal cell carcin-
oma treated with nivolumab and ipilimumab [35], we
consider the RAMONA dosage treatment scheme
with longer intervals of ipilimumab administration to
provide better tolerability (CheckMate 214 ipilimumab
Q3W as compared to Q6W in our study).
However, to ensure that patients are eligible for nivo-
lumab/ipilimumab combination therapy in the
RAMONA trial, a safety assessment is performed after a
3 week run-in phase of nivolumab alone. Only those pa-
tients with toxicities grade ≤ 2 will be escalated.
Taken together, we used the findings discussed
above to formulate the rationale of the RAMONA
study and to transfer current knowledge on im-
munotherapy to the fragile cohort of elderly Cauca-
sian ESCC patients. Overall survival was selected as
primary endpoint. In line, impressive long term re-
sponses of immunotherapy (at least with pembrolizu-
mab) of up to 50 months (median time to initial
response of 4 months (range, 2 to 8 months); median
DOR of 15 months (range, 6 to ≥26 months) are re-
ported, even after end of treatment [10]. Treatment
adherence is often negatively impacted by quality of
life (QoL) deterioration in cancer patients. Therefore,
adequate preservation of QoL is an important clin-
ical goal in in elderly patients with recurrent ESCC.
Thus, ‘Time to QoL Deterioration’ was included as a
key secondary endpoint in this trial.
Conclusion
In conclusion, RAMONA is the first trial to evaluate
checkpoint inhibitor based immunotherapy as a novel
treatment opportunity in elderly ESCC patients. Based on
a recruitment period of 12months, first results are ex-
pected end of 2019.
Trial status
RAMONA is an ongoing study. Recruitment com-
menced in April 2018 and the study is at the moment
recruiting patients. For a status update please refer to
https://clinicaltrials.gov/ct2/show/NCT03416244.
Additional file
Additional file 1: Table S1. RAMONA. Title of data: RAMONA synopsis.
Description of data: synopsis of the RAMONA trial. (DOCX 37 kb)
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